Table 2.
The immuno-histochemical findings and treatment outcomes in 43 adult patients with PCNSL
| Factor | ORRN (%) | P | CRN (%) | P | Median RFS (Mo) | P | Median OS (Mo) | P |
|---|---|---|---|---|---|---|---|---|
| Subtype of DLBCL | ||||||||
| - GCB | 8/9 (89) | 0.637 | 7/9 (78) | 0.136 | NR | 0.985 | NR | 0.003 |
| - Non GCB | 28/34 (82) | 17/34 (50) | NR | 14 | ||||
| BCL6 | ||||||||
| - Positive | 30/37 (81) | 0.244 | 19/37 (51) | 0.143 | NR | 0.842 | 17 | 0.534 |
| - Negative | 6/6 (100) | 5/6 (83) | NR | 12 | ||||
| Non GCB | ||||||||
| - Positive MUM1 | 25/31 (81) | 0.401 | 14/31 (45) | 0.070 | NR | 0.323 | 14 | 0.290 |
| - Negative MUM1 | 3/3 (100) | 3/3 (100) | NR | NR | ||||
| BCL2 | ||||||||
| - Positive | 32/39 (82) | 0.354 | 21/39 (54) | 0.417 | 17 | 0.075 | 15 | 0.271 |
| - Negative | 4/4 (100) | 3/4 (75) | NR | NR | ||||
| BCL2+ in GCB | 5/6 (83) | 0.710 | 4/6 (67) | 0.368 | NR | 0.255 | NR | 0.061 |
| BCL2+ in non GCB | 27/33 (82) | 17/33 (52) | NR | 14 | ||||
| MYC ≥40% | ||||||||
| - Yes | 10/10 (100) | 0.111 | 6/10 (60) | 0.761 | NR | 0.628 | 17 | 0.896 |
| - No | 26/33 (79) | 18/33 (55) | NR | 15 | ||||
| Double-expressor | ||||||||
| - Yes | 9/9 (100) | 0.137 | 5/9 (56) | 0.986 | NR | 0.628 | 14 | 0.834 |
| - No | 27/34 (79) | 19/34 (56) | NR | 17 | ||||
| Double-expressor | ||||||||
| - BCL6+ | 8/8 (100) | 0.167 | 4/8 (50) | 0.714 | 11 | 0.374 | 14 | 0.503 |
| - BCL6- | 28/35 (80) | 20/35 (57) | NR | 17 | ||||
| Ki67 ≥ 80% | ||||||||
| - Yes | 27/33 (82) | 0.539 | 18/33 (55) | 0.761 | NR | 0.790 | 17 | 0.897 |
| - No | 9/10 (90) | 6/10 (60) | NR | 14 | ||||
Abbreviations: GCB germinal center B cell, ORR overall response rate, CR complete remission rate, PFS progression free survival, OS overall survival, NR not reached